ANTIRETROVIRAL DRUG TREATMENT

Brand Owner (click to sort) Address Description
BIRIDA TEVA Pharmaceutical Industries Limited 124 Dvora HaNevi'a St. Tel Aviv 6944020 Israel antiretroviral drug for the treatment of HIV-1 infection;
BIRIDA TEVA PHARMACEUTICAL INDUSTRIES LTD. 124 Dvora HaNevi'a St. Tel Aviv 6944020 Israel antiretroviral drug for the treatment of HIV-1 infection;
LARIDA Teva Pharmaceutical Industries, Ltd. Science Based Indus. Campus, Har Hotzvim P.O.B.: 1142 Jerusalem 91010 Israel Antiretroviral drug for the treatment of HIV-1 infection;
RINATA TEVA Pharmaceutical Industries Limited 124 Dvora HaNevi'a St. Tel Aviv 6944020 Israel Antiretroviral drug for the treatment of HIV-1 infection;
TERANTE Teva Pharmaceuticals USA, Inc. Building A 400 Interpace Parkway Parsippany NJ 07054 Antiretroviral drug for the treatment of HIV-1 infection in adults;
TREATERA Teva Pharmaceuticals USA, Inc. Building A 400 Interpace Parkway Parsippany NJ 07054 Antiretroviral drug for the treatment of HIV-1 infection in adults;
TRIATET Teva Pharmaceuticals USA, Inc. Building A 400 Interpace Parkway Parsippany NJ 07054 Antiretroviral drug for the treatment of HIV-1 infection in adults;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), particularly treatment regimens including a protease inhibitor. The invention further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy using phenotypic or genotypic susceptibility assays.